Biotech Values

[rkrw]

Not on your list but another one that may or may not be resurrected, Dov Pharmaceutical. Private company raises $24M to buy a Dov compound for $2M and put it back into pivotal studies.

http://www.xconomy.com/boston/2010/07/22/euthymics-led-by-orexigen-vet-nabs-24m-for-depression-drug-with-fewer-side-effects/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Xconomy_San_Diego_Life_Sciences+(Xconomy+San+Diego+-+Life+Sciences)

http://dealbook.blogs.nytimes.com/2010/07/23/antidepressant-maker-taps-24-million/